BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 29719098)

  • 1. Allogeneic hematopoietic cell transplant following crizotinib monotherapy for relapsed/refractory anaplastic large cell lymphoma.
    John TD; Naik S; Leung K; Sasa G; Martinez C; Krance RA
    Pediatr Transplant; 2018 Aug; 22(5):e13210. PubMed ID: 29719098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma.
    Cleary JM; Rodig S; Barr PM; Shinagare AB; Clark JW; Shapiro GI; Armand P
    J Natl Compr Canc Netw; 2014 Mar; 12(3):323-6; quiz 326. PubMed ID: 24616538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of relapsed anaplastic large cell lymphoma with vinblastine monotherapy and allo-HSCT with reduced intensity conditioning regimen.
    Miyagaki S; Imamura T; Okumura Y; Ito I; Fujiki A; Osone S; Ishida H; Hosoi H
    Pediatr Int; 2015 Aug; 57(4):791-4. PubMed ID: 25847601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents--a Berlin-Frankfurt-Münster group report.
    Woessmann W; Peters C; Lenhard M; Burkhardt B; Sykora KW; Dilloo D; Kremens B; Lang P; Führer M; Kühne T; Parwaresch R; Ebell W; Reiter A
    Br J Haematol; 2006 Apr; 133(2):176-82. PubMed ID: 16611309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second allogeneic transplantation using umbilical cord blood for a patient with relapsed ALK+ anaplastic large cell lymphoma after allogeneic bone marrow transplantation in the era of ALK inhibitors: A case report.
    Saito S; Tashiro H; Sumiyoshi R; Matsuo T; Yamamoto T; Matsumoto K; Ooi J; Shirafuji N
    Medicine (Baltimore); 2021 Apr; 100(15):e25576. PubMed ID: 33847688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
    Mediwake H; Morris K; Curley C; Butler J; Kennedy G
    Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.
    Shustov A
    Best Pract Res Clin Haematol; 2013 Mar; 26(1):89-99. PubMed ID: 23768643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.
    Huang L; Zhang F; Zeng J; Guo H; Liu S; Wei X; Chen F; Jiang X; Liang Z; Liu Y; Li W
    Ann Hematol; 2018 Jan; 97(1):149-159. PubMed ID: 29150811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crizotinib in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma in the setting of renal insufficiency: a case report.
    Kothari S; Ud-Din N; Lisi M; Coyle T
    J Med Case Rep; 2016 Jun; 10():176. PubMed ID: 27301488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Successful allogeneic bone marrow transplantation with reduced intensity conditioning regimen for a pediatric relapsed ALK positive anaplastic large cell lymphoma].
    Hayase T; Niijima H; Tanaka D; Wada S; Kawahara Y; Oh Y; Morimoto A
    Rinsho Ketsueki; 2016 Jul; 57(7):859-63. PubMed ID: 27498729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of crizotinib for refractory ALK-positive lymphomas].
    Shelikhova LN; Fominykh VV; Abramov DS; Myakova NV; Maschan MA; Maschan AA
    Ter Arkh; 2017; 89(7):51-56. PubMed ID: 28766541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Successful bridging therapy with alectinib prior to allogeneic stem cell transplantation for refractory ALK-positive anaplastic large cell lymphoma].
    Kono A; Tanaka K; Shimada T; Bando K; Takahata A; Koi S; Yamamoto M; Mori T; Toyota S
    Rinsho Ketsueki; 2024; 65(3):158-163. PubMed ID: 38569859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematopoietic stem cell transplantation in relapsed ALK+ anaplastic large cell lymphoma in children and adolescents: a study on behalf of the SFCE and SFGM-TC.
    Strullu M; Thomas C; Le Deley MC; Chevance A; Kanold J; Bertrand Y; Jubert C; Dalle JH; Paillard C; Baruchel A; Lamant L; Michel G; Brugières L
    Bone Marrow Transplant; 2015 Jun; 50(6):795-801. PubMed ID: 25822227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients.
    Gambacorti Passerini C; Farina F; Stasia A; Redaelli S; Ceccon M; Mologni L; Messa C; Guerra L; Giudici G; Sala E; Mussolin L; Deeren D; King MH; Steurer M; Ordemann R; Cohen AM; Grube M; Bernard L; Chiriano G; Antolini L; Piazza R
    J Natl Cancer Inst; 2014 Feb; 106(2):djt378. PubMed ID: 24491302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
    Foyil KV; Bartlett NL
    Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children.
    Kada A; Fukano R; Mori T; Kamei M; Tanaka F; Ueyama J; Sekimizu M; Osumi T; Mori T; Koga Y; Ohki K; Fujita N; Mitsui T; Saito AM; Hashimoto H; Kobayashi R
    Acta Med Okayama; 2020 Feb; 74(1):89-94. PubMed ID: 32099255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial.
    Knörr F; Brugières L; Pillon M; Zimmermann M; Ruf S; Attarbaschi A; Mellgren K; Burke GAA; Uyttebroeck A; Wróbel G; Beishuizen A; Aladjidi N; Reiter A; Woessmann W;
    J Clin Oncol; 2020 Dec; 38(34):3999-4009. PubMed ID: 32730187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.